Cargando…

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA

BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive B-non-Hodgkin lymphoma with generally poor outcome. MCL is characterized by an aberrantly high cyclin D1-driven CDK4 activity. New molecular targeted therapies such as inhibitors of the ubiquitin-proteasome system (UPS) have shown promising res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heine, Simon, Kleih, Markus, Giménez, Neus, Böpple, Kathrin, Ott, German, Colomer, Dolors, Aulitzky, Walter E., van der Kuip, Heiko, Silkenstedt, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123978/ https://www.ncbi.nlm.nih.gov/pubmed/30180865 http://dx.doi.org/10.1186/s13045-018-0657-6

Ejemplares similares

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma
por: Dengler, M A, et al.
Publicado: (2014)

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
por: Leshchenko, Violetta V., et al.
Publicado: (2015)

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy
por: Silkenstedt, Elisabeth, et al.
Publicado: (2019)

Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells
por: Kleih, Markus, et al.
Publicado: (2019)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
por: Busacca, Sara, et al.
Publicado: (2013)

Correction: BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
por: Busacca, Sara, et al.
Publicado: (2013)

Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma
por: Quinet, Grégoire, et al.
Publicado: (2022)

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
por: Nguyen, Tri, et al.
Publicado: (2018)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
por: Zhao, Ling-Ling, et al.
Publicado: (2015)

The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma
por: Uziel, Orit, et al.
Publicado: (2014)

Cyclin K goes with Cdk12 and Cdk13
por: Kohoutek, Jiri, et al.
Publicado: (2012)

Molecular docking analysis of piperine with CDK2,CDK4,Cyclin D and Cyclin T proteins
por: Rekha, Umapathy Vidhya, et al.
Publicado: (2020)

Targeting cyclin D1 for mantle cell lymphoma
por: Chen, Jingtao
Publicado: (2015)

Nuclear Import of Cdk/Cyclin Complexes: Identification of Distinct Mechanisms for Import of Cdk2/Cyclin E and Cdc2/Cyclin B1
por: Moore, Jonathan D., et al.
Publicado: (1999)

Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
por: Kim, Areumnuri, et al.
Publicado: (2015)

Cyclin D1—Cdk4 regulates neuronal activity through phosphorylation of GABAA receptors
por: Pedraza, Neus, et al.
Publicado: (2023)

MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib
por: Wirth, Matthias, et al.
Publicado: (2014)

Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
por: Zhang, Wengang, et al.
Publicado: (2023)

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
por: Yang, David T, et al.
Publicado: (2008)

Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
por: Matsumoto, M, et al.
Publicado: (1999)

Ordered dephosphorylation initiated by the selective proteolysis of cyclin B drives mitotic exit
por: Holder, James, et al.
Publicado: (2020)

Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division
por: Clemm von Hohenberg, Katharina, et al.
Publicado: (2022)

3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma
por: Feng, Min, et al.
Publicado: (2021)

Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages
por: Cao, Lihuan, et al.
Publicado: (2014)

Structural insights into the functional diversity of the CDK–cyclin family
por: Wood, Daniel J., et al.
Publicado: (2018)

The awakening of the CDK10/Cyclin M protein kinase
por: Guen, Vincent J., et al.
Publicado: (2017)

Lineage specific composition of cyclin D–CDK4/CDK6–p27 complexes reveals distinct functions of CDK4, CDK6 and individual D‐type cyclins in differentiating cells of embryonic origin
por: Bryja, V., et al.
Publicado: (2008)

Proteolysis of Xenopus Cip-type CDK inhibitor, p16(Xic2), is regulated by PCNA binding and CDK2 phosphorylation
por: Zhu, Xi-Ning, et al.
Publicado: (2013)

DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex
por: Nakajima, Wataru, et al.
Publicado: (2016)

Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma
por: Liu, Hui, et al.
Publicado: (2008)

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells
por: Body, Simon, et al.
Publicado: (2017)

The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA
por: Muenchow, Alina, et al.
Publicado: (2020)

c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study
por: Fritz, Peter, et al.
Publicado: (2005)

Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma
por: Choi, Yun Jung, et al.
Publicado: (2019)

Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth
por: Qu, Fu-Lian, et al.
Publicado: (2015)

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
por: Jin, Jie, et al.
Publicado: (2018)

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis
por: Li, Shi-Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vbsmq1q6pbfv6vq8lg0aa1m8f4